Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 11% over the last three months. Since the market usually pay for a company's long-term fundamentals, we decided to study the company's key performance indicators to see if they could be influencing the market. In this article, we decided to focus on Regeneron Pharmaceuticals' ROE.
再生元制药公司（纳斯达克：REGN）股票在过去三个月中涨幅显著，达到11％。由于市场通常会为公司的长期基本面付费，因此我们决定研究公司的关键业绩指标，以确定它们是否可能影响市场。在本文中，我们决定重点关注再生元制药公司的ROE。
Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.
ROE（净资产收益率）是股东需考虑的一个重要因素，因为它告诉他们资本被有效地再投资的效果如何。换句话说，它揭示了公司将股东的投资转化为利润的成功程度。
How Is ROE Calculated?
净资产收益率怎么计算？
Return on equity can be calculated by using the formula:
股东权益报酬率可以使用以下公式计算：
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
净资产收益率 = 净利润（从持续经营中获得）÷ 股东权益
So, based on the above formula, the ROE for Regeneron Pharmaceuticals is:
因此，根据上述公式，再生元制药公司的roe为:
14% = US$3.9b ÷ US$27b (Based on the trailing twelve months to March 2024).
14% = US$3.9b ÷ US$27b（基于过去12个月至2024年3月）。
The 'return' is the profit over the last twelve months. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.14.
“回报”是指过去12个月的利润。这意味着，对于每1美元的股东投资，该公司将获得0.14美元的利润。
What Is The Relationship Between ROE And Earnings Growth?
既然我们已经确定ROE是一种有效的利润生成标准，用于评估公司未来的盈利能力，我们现在需要评估公司“保留”为未来增长而重新投资的利润多少，这使我们对公司的增长潜力有了一个了解。一般而言，在其他条件相等的情况下，ROE和利润留存高的公司，增长率比没有这些属性的公司要高。
Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
因此，我们已经了解到ROE衡量公司如何高效地创造利润。根据公司重新投资或“保留”的利润数量以及其有效性，我们随后能够评估公司的收益增长潜力。假设其他所有因素均保持不变，则ROE和利润保留率越高，相对于不一定具备这些特征的公司，公司的增长率就越高。
A Side By Side comparison of Regeneron Pharmaceuticals' Earnings Growth And 14% ROE
再生元制药公司盈利增长和14％的ROE比较
To start with, Regeneron Pharmaceuticals' ROE looks acceptable. Further, the company's ROE is similar to the industry average of 14%. Consequently, this likely laid the ground for the decent growth of 13% seen over the past five years by Regeneron Pharmaceuticals.
首先，再生元制药公司的ROE看起来是可以接受的。此外，该公司的ROE与行业平均水平14%相似。因此，这很可能为再生元制药公司过去五年所看到的13%的良好增长奠定了基础。
We then compared Regeneron Pharmaceuticals' net income growth with the industry and found that the company's growth figure is lower than the average industry growth rate of 16% in the same 5-year period, which is a bit concerning.
我们随后将再生元制药公司的净收入增长与行业进行了比较，并发现该公司的增长率低于同一5年期间平均行业增长率16％，这有点令人担忧。
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. Doing so will help them establish if the stock's future looks promising or ominous. Is REGN fairly valued? This infographic on the company's intrinsic value has everything you need to know.
评估公司价值的基础在很大程度上与其盈利增长有关。投资者需要判断的下一步是，预期的盈利增长（或缺乏盈利增长）是否已经反映在股票价格中。这样做可以帮助他们确定股票的未来前景是否看好或险象环生。REGN是否定价合理？该公司内在价值的信息图包含您需要知道的所有内容。
Is Regeneron Pharmaceuticals Making Efficient Use Of Its Profits?
再生元制药公司是否有效地利用其利润？
Regeneron Pharmaceuticals doesn't pay any regular dividends, meaning that all of its profits are being reinvested in the business, which explains the fair bit of earnings growth the company has seen.
再生元制药公司不支付任何定期股息，这意味着其所有利润都被重新投资于业务中，这解释了该公司所看到的相当多的盈利增长。
Summary
总的来说，我们对伟明环保的表现非常满意。具体而言，我们喜欢公司以高回报率再投资了其利润的很大一部分。当然，这导致公司的收益大幅增长。但是，最新的行业分析师预测表明，该公司的收益预计将加速增长。
Overall, we are quite pleased with Regeneron Pharmaceuticals' performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see a good amount of growth in its earnings. The latest industry analyst forecasts show that the company is expected to maintain its current growth rate. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
总的来说，我们对再生元制药公司的表现感到相当满意。具体来说，我们喜欢公司以高回报率重新投资其大量利润的做法。这当然导致了该公司收益的相当数量增长。最新的行业分析师预测显示，该公司预计将保持其当前的增长率。要了解有关该公司未来盈利增长预测的更多信息，请查看有关该公司的分析师预测的免费报告。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈？关于内容有所顾虑？直接和我们联系。或者，发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论，只使用公正的方法论，我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议，也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈？关于内容有所顾虑？直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。